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Abstract 
The mammalian target ofrapamycin (mTOR) kinase is a critical regulator of mRNA 
translation and is known to be involved in various long lasting forms of synaptic and 
behavioural plasticity. However, infonnation concerning the temporal pattern of mTOR 
activation and susceptibility to pharmacological intervention during both consolidation 
and reconsolidation oflong-term memory (L TM) remains scant. Male C57B L/6 mice 
were injected systemically wi th rapamycin at various time points fo llowing conditioning 
or retrieval in an auditory fear conditioning paradigm, and compared to vehicle (and/or 
anisomycin) controls for subsequent memory recall. Systemic blockade of mTOR with 
rapamycin immediately or 12 hours after training or reactivation impaired both 
consolidation and reconsolidation of an auditory fear memory. Further behavioural 
analysis revealed that the enduring effects of rapamycin on reconsolidation were 
dependent upon reactivation of the memory trace. Rapamycin, however, had no effect on 
short-term memory or the ability to retrieve an establ ished fear memory. Collectively, 
these data suggest that biphasic mTOR signalling is essential for both consolidation and 
reconsolidation-like activities that contribute to the fonnation, re-stabilization, and 
persistence of long tenn audi tory-fear memories, while not infl uencing other aspects of 
the memory trace. These findings also provide cogent evidence for a treatment model fo r 
acquired anxiety disorders such as posttraumatic stress disorder (PTSD) and specific 
phobias, through phannacologic blockade of mTOR using systemic rapamycin fo llowing 
reactivation. 
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l.O Introduction 
1.1 Molecular Mechanisms and Temporal Kinetics of Consolidation and 
Reconsolidation 
1 
Evidence that protein synthesis is necessary for memory consolidation has been 
demonstrated primarily through the use of protein synthesis inhibitors given around the 
time of~ or in the first few hours fo llowing, training (Cohen et a!., 2006; Davis & Squire, 
1984, Desgranges, Levy, & Ferreira, 2008; Meiri & Rosenblum, 1998; Milekic, Pollonini , 
& Alberini , 2007). Importantly, support for this conclusion has been very consistent 
across a variety of behavioural paradigms and species (Davis & Squire, 1984, McGaugh, 
2000). However, while protein synthesis dependency fo r long-term memory (L TM) 
fotmation has been well documented, more recent evidence suggests that there is at least 
a second wave of protein synthesis that is required for persistence of the engram (the 
postulated biochemical changes in neural tissue that represent a memory) under certain 
conditions (Bekinschtein et a!. , 2007a; Bourtchouladze et a!., 1998; Freeman, Rose, & 
Scholey, 1995; Grechsch & Matthies, 1980; Quevedo et a!. , 1999). In these studies at 
least two time periods of sensitivity to the amnestic etfects of the global protein synthesis 
inhibitor anisomycin (AN ISO) were contirrned, first around the time oftraining, and the 
second 3-5 (Bourtchouladze et a!. , 1998; Freeman, Rose, & Scholey, 1995; Grechsch & 
Matthies, 1980; Quevedo et a!., 1999) or 12 hours (Bekinschtein et a!., 2007a) post-
training. 
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Elucidation of events upstream, related to the expression and regulation of protein 
synthesis, including signalling cascades and mRNA synthesis, have become critical in 
furthering our understanding of the neurobiology ofleaming and memory. Similar to 
protein synthesis, many of these substrates and cascades are amenable to phannacological 
disruption (Bemabeu eta!., 1997; Lee, Everitt, & Thomas, 2004; Trifilieff eta!., 2006). 
Moreover, these upstream events, such as increased mRNA expression, or the activation 
of signalling cascades and growth factors, for example protein kinase A (PKA) or brain 
derived neurotrophic factor (BDNF) appear to parallel the same biphasic kinetic pattern 
and susceptibi lity to phannacological interventions as de novo protein synthesis in L TM 
fonnation and persistence (Bekinschtein eta!. , 2007a; Bemabeu eta!. , 1997; 
Bourtchouladze et a!. , 1998; Igaz, Vianna, Medina, & Izquierdo, 2002; Trifilieff eta!., 
2006; Trifilieff~ Calandreau, Herry, Mons, & Micheau, 2007). However, the temporal 
kinetics of certain signalling pathways that contribute to LTM f01mation and persistence, 
such as those involved in translational regulation, remain poorly understood. 
Once consolidated, memories are not impervious to disruption. Following 
reactivation, memories again appear to be susceptible to disruption by protein synthesis 
inhibitors and other types of pharmacological interference (Blundell, Kouser, & Powell, 
2008; Debiec & LeDoux, 2004; Duvarci, Nader, & LeDoux, 2008; Nader, Schafe, & 
LeDoux, 2000). This period of vulnerability following reactivation requires de novo 
protein synthesis tore-stabilize the engram, empirically defining the reconsolidation 
phase of memory (Nader et a!., 2000). Although this property of de novo protein 
synthesis-dependency is congruent with consolidation, it is unknown whether 
3 
reconsolidation recapitulates other mechanisms that constitute consolidation (Duvarci et 
al., 2008; Lee et al., 2004; Parsons, Gafford, & Helmstetter, 2006). Further, it is important 
to investigate whether time-sensitive properties of signalling events upstream of protein 
synthesis are also required for the re-stabilization of the memory trace after reactivation. 
Moreover, elucidation of the temporal parameters and molecular mechanisms of 
reconsolidation has significant clinical implications for identifying novel treatments for 
acquired anxiety disorders including post-traumatic stress disorder (PTSD) (Blundell et 
al., 2008; Debiec & LeDoux, 2006). 
1.2 PTSD and Fear Conditioning as a Model of PTSD 
PTSD is a functionally impairing anxiety disorder fo llowing exposure to an 
extreme traumatic stressor (event), and is characterized by the development of three 
clusters of symptoms (American Psychiatric Association (APA), 2000). The fi rst cluster 
of symptoms is characterized by the persistent re-experiencing of the traumatic event, 
which results in severe psychological distress and physio logical reactivity. This 
commonly occurs through recurrent intrusive recollections of the event, exposure to cues 
or symbols associated with the event, distressing dreams (nightmares), and more rarely 
through dissociative reliving of the event (fl ashbacks). The second cluster is marked by 
persistent avoidance of stimuli associated with the trauma and general emotional numbing 
in responsiveness to the external world. In this sense, individuals sutfering from PTSD 
will often experience anhedonia, emotional detachment, avoli tion, and deliberatel y avoid 
any event or symbol that can trigger recollection of the traumatic event. The fi nal cluster 
of symptoms is represented by chronic hyperarousal that was absent prior to the trauma; 
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which results in hypervigilance, itTitability, an exaggerated startle response, and diffi culty 
concentrating. 
Exposure to events that would be qualified as extremely traumatic in a 
community-based setting appears relatively high, with estimates ranging from 39.1 % 
(Breslau, Davis, Andreski, & Peterson, 199 1) to 8 1.3% (Stein, Walker, Hazen, & Forde, 
1997). From this population, a substantial subset of indi viduals will go on to develop the 
clinical symptoms of PTSD (Van Ameringen, Mancini, Patterson, & Boyle, 2008). 
Epidemiological studies have revealed the lifetime prevalence of PTSD to range from 
6.8% to 14% for the general adult population in the United States (APA, 2000; Kessler et 
a!., 2005). Similar in magnitude to the prevalence rates referenced above for the United 
States, albeit with a clear-cut paucity of and a need for more epidemiological studies in 
the Canadian context, the lifetime prevalence for PTSD is currently estimated to be 9.2% 
for the general population in Canada (Van Ameringen et a!. , 2008). While most 
indi viduals that present with the symptoms of PTSD actively seek out some sort of 
psychotherapy, pharmacotherapy, or both, only about 60 % of patients respond to these 
interventions (Onder, Tural, & Aker, 2006; Zohar et a!. , 2002), with onl y 20-30 % of 
patients achieving full remission (Berger et a!., 2009). 
Such an inequality in achieving fu ll remission, with only partial improvements 
and high refractoriness to treatment, underscores the need fo r novel therapeutic 
approaches. One such novel contemporary approach is a type of medication-enhanced 
psychotherapy that uses exposure therapy, the most efficacious type of psychotherapy fo r 
PTSD (Ballenger eta!., 2000; Frances, 1999), paired before or after with medication, with 
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the intention of disrupting reconsolidation or manipulating other psychological processes 
amenable to drug interference (Dunlop, Mansson, & Gerardi, 2012). Clinical trials for this 
type of therapy have mostly focused on alterations to the glucocorticoid and adrenergic 
signalling systems, however, further randomized, double-blind clinical studies delineating 
the precise effectiveness of such interventions are still required (de Quervain & Margraf, 
2008; Dunlop et al., 2012; Poundja, Sanche, Tremblay, & Brunet, 2012). 
Much of what has influenced this phannacological adjunct to exposure therapy 
emanates from pre-clinical studies examining the neurobiology of learning and memory 
(Dunlop et al. , 20 12). Investigations concerned with the neurobiology of reconsolidation 
through Pavlovian fear conditioning have discovered important infonnation about the 
molecular mechanisms of memory, in addition to providing putative clinical therapeutic 
targets. Moreover, the most efficacious psychotherapy for PTSD, exposure therapy, is 
!:,'TOunded in the principles of Pavlovian fear conditioning. However, while fear 
conditioning accurately models the exaggerated fear response that accompanies 
recollection of the traumatic event, it does not model the other cardinal, non-associative 
features of PTSD such as increased startle or hypervigilant behaviours (Sie!:,rrnund & 
Wotjak, 2006). Despite these shortcomings, fear conditioning facilitates the systematic 
examination ofthe molecular mechanisms of memory, and the development and testing 
of phannacological agents that act on reconsolidation. Thus, fear conditioning provides 
robust translational potential for identifying novel clinical pharmacological opportunities 
to couple with reactivation of the traumatic memory (through exposure therapy) to 
potentially reduce the core symptoms of PTSD, while also providing insight into the 
neurobiology of learning and memory, such as examining the role of the translational 
regulator mammalian target of rapamycin (mTOR) in the consolidation and 
reconsolidation of memory. 
1.3 Translational Regulation by mTOR in Long-lasting Forms of Behavioural and 
Synaptic Plasticity 
6 
MTOR, a serine/threonine protein kinase, controls the initiation and capacity of a 
subset ofmRNA translation in neurons primarily through phosphorylation oftwo 
downstream targets, phosphorylated70-kDa ribosomal s6 kinase (p70s6K) and eukaryotic 
initiation factor 4E-binding protein I (4EBP1) (Hay & Sonenberg, 2004; Raught, Gingras 
& Sonenberg, 2001). Previous research using rapamycin (RAP), a selective inhibitor of 
the mTOR kinase, has found that mTOR is a critical constituent of activity-dependent 
synaptic plasticity in a range of preparations (Casadio et a!., 1999; Gong eta!., 2006; 
Tang eta!. , 2002). Further, the mTOR pathway appears to be engaged following a variety 
of fear-motivated and non-fear-motivated learning paradigms, exhibiting increased 
p70s6K expression in hippocampo-amygdalar nuclei (Bekinschtein et a!., 2007b; Dash, 
Orsi, & Moore, 2006; Glover, Ressler, & Davis, 20 I 0; Parsons eta!., 2006) . Akin to the 
effects on activity-dependent synaptic plasticity, which are the electrophysiological 
correlates of memory, treatment with RAP around the time of training has elucidated a 
fundamental role for the mTOR pathway in consolidation of several fonns of memory 
(Bekinschtein eta!., 2007b; Blundell eta!., 2008; Dash eta!. , 2006; Glover eta!. , 20 I 0; 
Jobim eta!., 20 12a). As well , translational regulation through the mTOR pathway also 
appears to be essential in reconsolidation of the engram fo llowing retrieval. Trained 
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animals exhibit increased levels of p70s6K following retrieval (Gafford, Parsons, & 
Helmstetter, 2011 ), while mTOR blockade using RAP following reactivation disrupts 
subsequent retention under certain conditions (Blundell et al. , 2008; Gafford et al. , 20 I 1; 
Glover et al. , 2010; Jobim et al. , 201 2a; Jobim et al. , 20 12b; Myskiw et al. , 2008; Parsons 
et al., 2006). 
While it is well known that RAP blocks consolidation and reconsolidation of 
contextual fear memory (Bekinschtein et al. , 2007b; Blundell et al. , 2008; Gafford et al. , 
20 11 ; Glover et al. , 20 1 0; Jobim et al. , 20 12a; Parsons et al. , 2006), its effects on cue-
based fear memory are far less consistent (Gafford et al. , 2011 ; Glover et al., 201 0; 
Parsons et al. , 2006). When RAP is directly infused into the amygdala (bilaterally at a 
volume of 0.5 J ... d /side, using a dose of 5 J.lg/J...tl for consolidation, and 1 J.lg/J.l l for 
reconsolidation) it negatively affects cue-based fear memory formation and 
reconsolidation (Parsons et al. , 2006). Conversely, direct infusion into the hippocampus 
(bilaterally at a volume of I f.lllside, using a dose of 5 J.lg/f.ll) fails to disrupt consolidation 
(Gafford et al. , 20 11 ), whi le systemic RAP treatment ( 40 mg/kg) fai ls to attenuate both 
consolidation and reconsolidation of fear-potentiated startle to an odour-conditioned 
stimulus, which is a cued-based Pavlovian fear memory (Glover et al. , 20 I 0). As a result, 
it is unclear whether systemic RAP treatment would attenuate auditory fear memory- a 
cue-based fear memory. Moreover, with the exception of only one other published study 
to date (S iipczuk et al. , 2009), the time course for mTOR regulation of translation in 
conso lidation is not known. Slipczuk et al. (2009) described two distinct windows of 
mTOR activation at the moment of, or three hours post-training, in an inhibitory 
avoidance task, and that intra-hippocampal treatment with RAP at these distinct time 
periods effaced subsequent retention. In contrast, to the best of my knowledge, no 
published studies have examined the temporal pattern of activation and susceptibility of 
mTOR in reconsolidation of memory. 
1.4 Goals and Aims 
8 
The aim of the present study was to determine if a single systemic injection of 
RAP would disrupt consolidation and reconsolidation of an auditory fear memory in a 
time-dependent manner after training or retrieval, and whether these effects would be 
enduring. Herein, it was demonstrated that systemic inhibition of mTOR with RAP, 
during two critical periods of sensitivity, blocked both consolidation and reconsolidation-
1 ike activities that contribute to the formation, retention, and maintenance of L TM, while 
sparing retrieval and short-term memory (STM). Overall , the data suggest that biphasic 
translational control through the mTOR pathway is normally required during the long-
tenn fom1ation and stabilization of memory through recurrent consolidation and 
reconsolidation-like events. 
2.0 Materials and Methods 
2.1 Animals 
A total of 390 male, approximately 7 to 8 week-old C57BL/6 mice (Charles Ri ver 
Laboratories, St Constant, QC, Canada), were used for these experiments. Mice were 
group housed with 4 mice per cage, and had ad Libitum access to food and water in 
standard laboratory conditions on a 12 hour light-dark cycle (lights on at 7 a.m., lights off 
9 
at 7 p.m.). Prior to and during the course of experiments, all animals w'ere handled dai ly 
for identification marking with non-toxic markers and routine husbandry duties during the 
light-phase of their cycle. Mice were transported from the animal housing facility to an 
I 
anteroom, adjacent to the testing room and allowed to habituate to the new location for a 
minimum of one hour prior to training and testing. All behavioural testing and 
experimental manipulations were conducted during the light-phase of their cycle unless 
stated otherwise. 
All procedures and protocol for experiments and animal housing were foll owed 
pursuant to the guidelines of the Canadian Counsel on Animal Care and Memorial 
University ofNewfoundland's Animal Care Committee. 
2.2 Behaviour 
All mice from a particular cage were run simultaneously in separate chambers for 
training and testing. Each fear conditioning chamber contained a 26 grid shock floor, with 
transparent Plexiglas front and rear walls, situated within a sound attenuating isolation 
cubicle (Habitest, Coulbourn Instruments, Whitehall , Pennsylvania). For all training 
sessions, mice were placed in the conditioning chamber for a 120-s habituation period 
before the two identical conditioning trials began (except for Experiment 2, see below for 
I 
additional details). This habituation period was followed by a continuous 30-s, 80 dB 
tone. During the last 2 seconds of tone presentation, a 0.6 mA foot shock was delivered 
and co-tenninated with the auditory cue. An inter-trial interval of 60-s preceded a second 
identical trial. Mice remained in the chamber for an additional 120-s after the second 
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shock betore being returned to their home cages. To test for cued-fear memory after 
varying intervals (determined by the specific experiment below), animals were placed in 
conditioning chambers with different tactile, visual and olfactory configurations than the 
original conditioning context (wooden floor over grid platform, cardboard and electrical 
tape along the walls, and vanilla extract wiped over the chamber) and their freezing 
behaviour in response to the auditory cue was measured. Mice were habituated to the 
altered test chambers for the first 3 minutes, after which the same continuous tone from 
training was presented for an additional 3 minutes betore the mice were removed from the 
testing chambers. All probes of cued-fear memory tor both retrieval and reactivation 
sessions were identical in procedure, with freezing behaviour - the absence of movement, 
except for respiration - being measured throughout using automated software 
(FreezeFrame, Coulbourn Instruments, Whitehall, Pennsylvania). Chambers were cleaned 
with 10% ethanol and allowed to air-dry between mice. 
2.3 Experiments 
2.3.1 Experiment 1 - Evaluating the associability of an auditory fear 
conditioning protocol. Two groups of mice were trained as described above. However, 
only one group received the two-trial, tone-shock, conditioning paradigm (tone-shock 
(TS), n = 12). The control group was presented with just the tone, omitting the co-
terminating footshock for both conditioning trials (no shock (NS), n = 4). To determine 
the associability tor this cued-learning protocol, animals were testing for memory to the 
auditory tone in a novel chamber forty-eight hours fo llowing training. 
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2.3.2 Experiment 2 - Determining the optimal frequency of tone-shock trials 
to maximize the conditioned response. Four groups of mice received single session 
auditory fear training, with each group receiving a different number of di screte tone-
shock pairing trials. A ll training sessions fo llowed the parameters and sequence pattern 
established in the previously described training protocol for time allotted to habituate, 
duration and tem1ination of stimuli used to condition, inter-trial interval duration, and 
time allotted at the end of the training session to return behaviour to baseline. However, 
the number of tone-shock trials and hence total time within the conditioning chambers for 
each group of animals was systematically altered. Mice received 2 (2-TS, n =8), 3 (3 -TS, 
n = 8), 4 (4-TS, n = 8), or 5 (5-TS, n = 8) tone-shock trials, for a total training session of 
360, 450, 540, or 630-s respectively. Forty-eight hours post training, freez ing behaviour 
was measured in a novel chamber to assess the magnitude of the cued-fear memory, as 
described above. 
2.3.3 Experiment 3- Effects of post-training systemic rapamycin on auditory 
fear memory consolidation. Upon removal from each chamber fo llowing training, mice 
were immediately injected wi th either RAP ( 40.0 mg/kg, n = I I) or vehicle (VEH) (n = 
11 ). Forty-eight hours later, cued-fear memory was assessed as described above. 
2.3.4 Experiment 4 - Short-term memory response to post-training mTOR 
blockade. Upon removal from each chamber fo llowing training, mice were injected with 
either RAP (40.0 mg/kg, n = 12) or VEH (n = 10). One hour later, STM for the 
conditioned-tone was examined in a novel chamber (as described above, 3 min 
habituation followed by 3 min presentation of the conditioned tone). Forty-eight hours 
later, memory for the conditioned-tone was again vetted in the same chamber. 
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2.3.5 Experiment 5- Effects of mTOR blockade immediately prior to 
retrieval of an established fear memory. Two days following training, 30 minutes prior 
to retrieval mice were injected with either RAP ( 40.0 mglkg, n = 12) or VEH (n = 12). 
Mice were then re-exposed to the conditioned-tone in a novel chamber to assess whether 
RAP disrupts retrieval of an established fear memory. 
2.3.6 Experiment 6 - Determining whether the effects of rapamycin on 
auditory fear memory consolidation are enduring. Immediately following training, 
animals were injected with either RAP ( 40.0 mglkg, n = 12), AN ISO ( 150.0 mglkg, n 
= 12), or VEH (n = 12). Three weeks later, memory for the conditioned-tone was tested in 
a novel chamber to determine the long-term effects of RAP on fear memory. 
2.3.7 Experiment 7 - Effects of mTOR blockade at varying intervals post-
acquisition on long-term memory. Mice received injections of RAP ( 40.0 mglkg) or 
VEH at 3 hours (RAP-3 , n = 12; VEH-3, n = 12), 12 hours (RAP-1 2, n = 12; VEH-1 2, n 
= I I), or 24 hours (RAP-24, n = 12; VEH-24, n = 12) post-training. Injections at the 12 
hour delay occurred during the dark phase of the light-dark cycle. Forty-eight hours after 
training, memory for the conditioned-tone was assessed for all mice in a novel chamber. 
2.3.8 Experiment 8 - Long-term memory response to rapamycin treatment 
18-hours following training. During the dark phase of their light-dark cycle, mice either 
received a single injection of RAP ( 40.0 mglkg, n = II) or VEH (n = II ) 18 hours after 
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training. Forty-eight hours after training, freezing behaviour to the conditioned-tone was 
measured in a novel chamber to examine any general interaction effects from changes in 
circadian rhythms and treatment with RAP on memory consolidation. 
2.3.9 Experiment 9 - Effects of post-retrieval systemic rapamycin on auditory 
fear memory reconsolidation. Two days after training, mice were re-exposed to the 
conditioned-tone in a novel chamber. Upon removal from the chambers after reactivation, 
mice received either RAP (40.0 mg/kg, n = 15) or VEH (n = 14). One day later, cued-
fear memory was assessed to determine if RAP blocks reconsolidation. 
2.3.10 Experiment 10 - Effects of mTOR blockade in the absence of retrieval 
on subsequent recall. Two days following training, animals were injected with either 
RAP (40.0 mg/kg, n = 12) or VEH (n = II). However, unlike Experiment 9, mice were 
not re-exposed to the conditioned-tone, but simply returned to their home cages 
immediately after injections. Twenty-four hours after injections, mice were assessed for 
cued-fear memory to the conditioned-tone in a novel chamber. 
2.3.11 Experiment 11 - Evaluating the long-lasting effects of post-retrieval 
mTOR blockade on an established memory trace. Memory for the conditioned-tone 
was reactivated in a novel chamber 48 hours after training. Immediately after reactivation, 
mice received an injection of RAP ( 40.0 mg/kg, n = 12), AN I SO (!50 mg/kg, n = 12), or 
VEH (n = 12). Three weeks after reactivation, mice were measured for freezing to 
determine the long-term effects of RAP on reconsolidation of cued-fear memory. 
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2.3.12 Experiment 12 - Effects of rapamycin treatment at varying intervals 
post-retrieval to long-term memory. Two days post-training, mice were re-exposed to 
the conditioned-tone in a novel chamber. Mice were then injected with RAP (40.0 mglkg) 
or VEH at either 12 hours (RAP-12, n = 12; VEH-12, n = 11), or 24 hours (RAP-24, n = 
12; VEH-24, n = 12) post-reactivation of the cued-fear memory. Injections at the twelve 
hour delay occurred during the dark phase of the light-dark cycle. Forty-eight hours after 
reactivation, freezing was measured to assess the effect of RAP on the reconsolidation of 
auditory-fear memory. 
2.3.13 Experiment 13- Effects of mTOR blockade 18-hours after retrieval to 
an established fear memory. Fear memory for the conditioned-tone was reactivated in a 
novel chamber 48 hours after training. Mice were then injected with RAP ( 40.0 mglkg, 
RAP-1 8, n = 12) or VEH (VEH-18, n = 12) 18 hours after reactivation during the dark 
phase of their light-dark cycle. Forty-eight hours after reactivation, fear memory for the 
tone was assessed to determine any non-specific interaction effects from circadian rhythm 
changes and RAP treatment on reconsolidation of the engram. 
2.4 Drug Preparation/ Administration 
Immediately prior to experimentation fresh solution of drug was made by 
dissolving RAP or AN ISO in a vehicle of 5% ethanol, 4% PEG 400, and 4% Tween 80 
in distilled water. Mice received intraperitoneal injections ofVEH, RAP, or AN ISO in 
volumes ranging from 0.2 to 0.3 ml based on their weight. The RAP dosage of 40 mglkg 
and AN ISO dosage of 150 mglkg are based on previous studies that demonstrated 40 
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mg/kg and 150 mg/kg respectively, to have the most efficacy at disrupting contextual 
fear-memory, while conserving normal locomotion and nociception (Blundell et al. , 2008, 
Cai, Blundell, Han, Greene, & Powell, 2006). 
2.5 Statistics 
Mixed Analysis of Variance (ANOVA) and post hoc Fisher's Least Significant 
Difference (LSD) tests were used for experiments with multiple groups or requiring 
multiple comparisons. A priori t- tests were used for follow up two-group comparisons. 
Freezing data for statistical analysis were obtained from fear memory probes by taking 
the difference in percent freezing during tone activation (latter 3 minutes oftest) from 
percent freezing during no tone presentation (tirst 3 minutes of test), to obtain a measure 
of freezing to the conditioned tone that accounts for any non-specific freezing behaviour. 
Freezing data were also obtained from training sessions (first 2 minutes of training; time 
immediately prior to the first conditioning trial), thus, allowing for within group 
comparisons of freezing behaviour across training and memory probe days (within 
subjects main effect of day in the mixed AN OVA design). Significance was taken asp < 
0.05. 
3.0 Results 
3.1 Two-Trial, Cued Fear Conditioning Optimizes Associability (Exp. 1) and 
Maximizes the Auditory Fear Memory Response (Exp. 2) 
Prior to examining the effects of RAP on cued-fear memory, the robustness of the 
chosen behavioural procedure to produce fear conditioning was tirst continned. To 
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determine this, two groups of mice were trained in a single session, two-trial auditory fear 
conditioning task, and tested for retention 48 hours later. Both groups received an equal 
number of trials and exposure to the conditioning tone during training, however, only one 
srroup received the co-terminating shock with each trial (TS group), while the control 
group was spared exposure to the foot-shocks (NS group). A mixed ANOVA revealed a 
significant change in freezing behaviour following re-exposure to the conditioning tone in 
the novel chambers [main effect of condition, day, and interaction effect of condition and 
day, all Fs ( I, 14) > 20.386, p < .001]. Follow-up t-tests on freezing behaviour observed 
during memory testing showed that only those animals that received the tone-shock 
pairing during training demonstrated successful associative learning relative to their NS 
training counterparts [Fig l a; t (14) = -4.515, p < .001]. It should be noted that while 
statistical analyses are principally based on percent freezing to the conditioned tone 
during test, corrected for any spontaneous fi·eezing, the baseline level of freezing 
(freezing during the first 3 minutes in the testing chamber prior to tone activation) was 
also separately analyzed to evaluate any change in spontaneous freezing behaviour for 
each experiment, as well as for any differences in percent freezing during training. 
Importantly, no differences in freezing behaviour were observed during training (2 min 
habituation period or 2 min post shock) or during the baseline period(s) for fear-memory 
testing (first 3 min without tone present) across groups in all experiments (1-13), 
indicating unaltered spontaneous behaviour or differences during training (data not 
shown, all p > .05). 
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To assess whether a greater magnitude freezing response could be el icited, mice 
were trained using the above procedure, but instead of just 2 trials, animals received 2, 3, 
4, or 5 trials of the tone-shock pairing, and were tested for fear memory to the auditory 
cue 48 hours later. A mixed ANOV A revealed a significant main effect of day [F (I , 28) 
= 347.433, p < .001], indicating successful learning in all groups; but no significant main 
effect of number of trials, or interaction effect of number of trials and day [all Fs (3, 28) < 
1.447, p >.250]. Although the data indicate an initial trend of increased freezing to the 
conditioned tone as a function of increasing the number of conditioning trials, this 
tendency was not significant and diminished after the four-trial training procedure (Fig 
I b). As a result, the two-trial, conditioning procedure was employed for all subsequent 
experiments, since this procedure was sufficient at achieving maximal freezing to the 
conditioned tone. 
3.2 Systemic Rapamycin Blocks Auditory Fear Memory Consolidation (Exp. 3), but 
Not Short-Term Memory (Exp. 4) or Retrieval (Exp. 5) 
To determine whether systemic administration of RAP would affect auditory fear 
memory consolidation, mice were trained in the auditory fear conditioning task. 
Immediately after training, animals were injected with either RAP or VEH and tested for 
auditory fear memory 48 hours later. A mixed ANOVA revealed significant dampening 
of fear expression (decreased freezing) upon re-exposure to the conditioned-tone [main 
effect of drug F (1 , 20) = 4 .553, p = .045, main effect of day F ( I, 20) = 67.807, p < .00 I, 
interaction effect of drug and day F ( 1, 20) = 4.553 , p = .045]. Follow up t-test revealed 
that RAP-treated animals exhibited significantly less freezing than VEH-treated animals 
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when prompted by the conditioned-tone during memory testing [Fig 2a; t (20) = -2.1 34, p 
= .045]. 
To detennine if the effects of RAP on auditory-fear memory were indeed the 
result of disrupting consolidation and not from alterations to other aspects of the memory 
trace, mice were injected immediately after training with either RAP or VEH. One hour 
later, memory for the cued-tone was evaluated in a novel chamber, and again 48 hours 
after training. A mixed ANOV A of a three time points (training, reactivation, and test) 
revealed a significant main effect of day [F (2, 40) = 27.240, p < .00 I], and an interaction 
effect of drug and day [F (2, 40) = 4.098, p =.024]. In follow up t-tests, memory in both 
t,Tfoups were comparable when tested one-hour following training - indicative of normal 
acquisition and STM [Fig.2b left panel; t(20) = 0.054, p = .958). However, while short-
term memory was spared, long-tem1 memory was signifi cantl y decreased in RAP-treated 
animals relative to controls when tested 48 hours after training [Fig. 2; t(20) = 2.225, p = 
.038], consistent with data from Experiment 3 (See Fig. 2a). 
The half-life of RAP in circulation of mice is between 4 and 6 hours (Baker, 
Sidorowicz, Sehgal, & Vezina, 1978), thus, the drug has been fully excreted when the 
fear-memory is challenged during recall 48 hours after training and drug injection (See 
Figs. 2a & b). Accordingly, the observed disruption to long-term memory from RAP 
treatment should not be the result of a direct effect of RAP resulting in an inability to 
retrieve the memory trace when prompted. To be ce1iain that RAP was not impinging on 
the ability to retrieve the memory trace, mice were treated with RAP or vehicle 30 
minutes prior to a fear-memory probe, 48 hours after training. A mixed ANOV A revealed 
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that RAP infusion immediately before recall does not significantly affect retrieval [Fig.2c; 
main effect of day F (1 , 22) = 130.023, p < .00 I, but no significant main effect of drug or 
drug by day interaction, all Fs (I , 22) < 0.8 16, all p > .05]. 
3.3 The Effects of Rapamycin on Auditory Fear Memory Consolidation are Not 
Long-Lasting (Exp. 6) 
To determine if block of consolidation by RAP is long-lasting (comparable to that 
of AN ISO, Latta! & Abel, 2004), mice were injected with RAP, ANISO, or VEH 
immediately after training, and tested for auditory fear-memory 2 1 days later. A mixed 
AN OVA revealed a main effect of drug [F (2, 33) = 16.056, p < .001 ], main effect of day 
[F (l , 33) = 84.533, p < .001 ], and interaction effect of drug and day [F (1, 33) = 14.915, 
p < .00 I]. Post hoc Fisher's LSD tests revealed that auditory fear memory was 
si!:,rnificantly effaced in ANISO-treated animals relative to all other groups, which showed 
nonnal amounts of freezing [Fig.3; AN ISO vs. RAP, p < .00 1; AN ISO vs. VEH, p < .001; 
RAP vs. VEH, p = .529]. 
3.4 Long-Term Memory is Susceptible to Rapamycin at Twelve Hours After 
Acquisition (Exp. 7 and 8) 
It has previously been demonstrated that the consolidative process for a variety of 
learning tasks has a varied and often multi-phasic temporal sensitivi ty depending on the 
molecular or cellular substrate being investigated (Bekinschtein et al. , 2007a; Trifilieff et 
al; 2007). However, characterization of the temporal dynamics of mTOR signalling in 
auditory fear-memory consolidation has not been fully examined. To detennine if the 
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consolidative process is temporally susceptible to mTOR blockade, the effects of 
systemic RAP treatment were examined at various times following training. Mice 
received single intraperitoneal injections of RAP or VEH at 3, 12, or 24 hours post-
training, and were subsequently tested for auditory fear memory 48 hours after training. 
Results of a mixed ANOV A revealed a significant main effect of drug [F (l, 65) = 6.338, 
p = .014] and main effect of day [F (I , 65) = 158.254, p < .001] , but no main effect of 
time injected [F (2, 65) = 4.12, p = .664]. Follow-up t-tests showed that RAP attenuated 
memory for the conditioned-tone at 12, but not at 3 or 24 hours post-training [Fig.4; t (21) 
= 2.253, p = .035; t (22) = 0.645, p = .526; t (22) = 1.419, p = .170, 12 hours, 3 hours, and 
24 hours respectively]. Moreover, it is important to note that the effects of RAP on 
consolidation 12 hours post-training did not result from non-specific changes in circadian 
rhythms interacting with RAP, as there were no effects of RAP treatment 18 hours post-
training [mixed ANOYA: main etfect of day F (1 , 20) = 97.464, p < .001, but no main 
effect of drug F (I , 20) = 3.256, p = .086, and no interaction effect of day and drug F (l , 
20) = 3. 192, p = .089]. Thus, these tindings illustrate that the fonn ation and persistence 
of LTM storage require the mTOR signalling pathway. 
3.5 Systemic Blockade of mTOR Disrupts Auditory Fear Memory Reconsolidation 
(Exp. 9 and 10) 
To detennine if the mTOR pathway is required for the stabil ity of the memory 
trace in an auditory tone-shock association, mice were treated with RAP or VEH 
immediately fo llowing memory reactivation and tested 24 hours later (i.e.72 hours after 
training). A mixed ANOY A revealed a significant main effect of day [F (2, 54) = 45.573, 
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p < .001 ], and a significant interaction etTect of drug and day [F (2, 54)= 4.206, p = 
.020], while the main effect of drug approached, but did not reach significance [F (I, 27) 
= 3.659, p = .066]. As expected, forty-eight hours after training, re-exposure to the 
conditioned-tone resulted in robust freezing in both groups, indicative of successful 
learning [Fig.Sa; t-test: t (27) = 0.151 , p = .881]. However, animals given RAP 
immediately after recall expressed a significantly diminished fear response compared to 
VEH-treated controls 24 hours later [Fig. Sa; t-test: t (27) = -2.817, p = .009]. 
Importantly, this attenuation of an established fear memory was not merely an effect of 
RAP treatment alone. In the absence of reactivating the auditory fear memory, RAP alone 
had no effect on subsequent memory recall when tested 24 hours after drug treatment, 72 
hours after training [Fig.Sb; mixed ANOVA: main effect of day F (l , 22) = 142.387, p < 
.00 I, but no significant main effect of drug or drug by day interaction [all Fs (1, 22) < 
1.661 , all p >.05]. 
3.6 Rapamycin has Enduring Effects on an Established Memory Trace (Exp. 11) 
A single systemic post-reactivation injection of RAP can attenuate contextual fear 
memory in a long-lasting manner that is significantly stronger than AN ISO (Blundell et 
al. , 2008). Thus, it was next determined whether these effects could be extended to 
auditory fear-memory. To do this, mice were trained, and 48 hours later memory was 
reactivated. Immediately after reactivation, mice received a single systemic injection of 
RAP, AN ISO, or VEH. Twenty-one days later, mice were tested for cue fear memory 
recall. Vehicle-treated animals exhibited nonnal freezing behaviour, while RA P and 
ANISO-treated animals showed significantl y reduced freezing to the conditioned-tone 
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[Fig.6; mixed AN OVA: main effect of drug F(2, 33) = 3.609, p = .038, main effect of day 
F (2, 66) = 45 .396, p < .00 I, interaction effect of drug and day F ( 4, 66) = 1.853, p = .129; 
Post hoc Fisher's LSD tests: VEH vs. RAP, p = .018, VEH vs. ANISO, p = .042, RAP vs. 
ANISO, p = . 71 0]. Collectively, these findings delineate a role for mTOR signalling in 
the reconsolidation and the long-term persistence of an auditory fear memory trace. 
3.7 Established fear memory is labile to rapamycin at twelve hours post-reactivation 
(Exp. 12 and 13) 
Consolidation and reconsolidation are fairly congruent with regards to molecular 
signalling cascades. Thus, the next experiment attempted to elucidate whether 
reconsolidation recapitulates the same temporal pattern of susceptibility to systemic RAP 
as consolidation (See Fig.4). To assess for critical periods ofmTOR activity following 
reactivation of an establi shed memory, animals were injected with RAP or VEH at either 
12 hours or 24 hours (negative comparison group) post-reactivation. Forty-eight hours 
after re-exposure, animals were tested again for recall. As expected, there were no 
significant differences between groups during reactivation of the memory trace (no data 
shown, t-tests, all p > .05). However, animals treated with RAP at 12 hours post-
reactivation displayed significantly decreased memory when tested 48 hours later, while 
no effect was observed in the 24 hour post-reactivation injection group during test 
[Fig.7A & B respectively; mixed ANOVA : main effect of drug F (1 , 43) = 4.078, p = 
.050, main effect of day F (2, 86) = 89.903, p < .001, main effect of time injected F ( 1, 
43) = .003, p = .960; fo llow up t-tests: t (2 1) = 2.460, p = .023, t (22) = 0.1 90, p = .85 1, 
12 delay and 24 hour delay, respectively]. Importantly, the effects of RAP treatment on 
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reconsolidation 12 hours post-reactivation were not artefacts of RAP interacting with 
circadian rhythm changes ofthe animal, as RAP treatment 18 hours post-recall did not 
alter subsequent memory [mixed ANOVA: main effect of day F (2, 44) = 76.34, p < .00 1, 
no significant main effect of drug F ( 1, 22) = 3 .272, p = .084, or interaction effect of day 
and drug F (2, 44) = 2.435, p = .094]. Again, there was no significant difference between 
groups during reactivation of the memory trace (data not shown, t-test, p > .05). Thus, 
following reactivation, initial re-stabilization and persistence of long-tenn memory 
storage requires the mammalian target of rapamycin. 
4.0 Discussion 
Single, systemic administration of RAP, either immediately following or 12 hours 
post-training or post-memory reactivation impairs both consolidation and reconsolidation 
of an auditory fear memory. Importantly, RAP effects on memory are not artefacts of 
RAP interacting with changes in circadian rhythms, as treatment at 18 hours post-training 
or reactivation did not disrupt subsequent memory recall (See sections 3.4 & 3.7). Thus, 
this data indicates that at the very least, biphasic mTOR signalling within 24 hours of 
post-training or post-retrieval is critical for both the consolidation and reconsolidation of 
LTM. 
4.1 Consolidation of Auditory Fear Memory 
These results add to a growing volume of evidence indicating that mTOR-
mediated regulation of protein translation is a critical mechanism in facilitating 
consolidation. Parsons and colleagues (2006) were the first to demonstrate impaired 
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auditory fear memory retention following intra-amygdalar infusion of RAP (5 11gl111) 
immediately following training in rats. These results reported here are in concert with 
their findings. However, the present findings demonstrate that RAP affects consolidation 
and not other aspects (e.g. acquisition & retrieval) of the auditory fear memory trace (See 
section 3 .2); since immediate post-training blockade of mTOR fails to disrupt acquisition 
of auditory fear, as evidenced by the amount freezing I hour after training, while still 
impairing memory 48 hours after training. Furthermore, RAP treatment prior to recall 
does not impair the ability of the animal to retrieve the memory trace. Finally, these 
findings provide evidence of systemic efficacy at a dose that does not appear to cause 
noticeable effects on pain sensitivity, anxiety, or locomotor activity (Blundell eta!. , 
2008). Thus, these results confirm and extend previous findings indicating RAP disrupts 
auditory fear memory fonnation, but not other aspects of the memory trace. 
It was also demonstrated that RAP infusion at 12 hours post-training has 
deleterious effects on fear memory when probed 48 hours after learning. This is in direct 
contrast to recent findings that RAP treatment (bilaterally into the dorsal hippocampi in a 
vo lume of 0.5 111/side, using a dose of 5 pgl 11l) at 12 hours post-training does not alter 
fear memory consolidation and expression (Bekinschtein eta!. , 2008; Slipczuk eta!., 
2009). Rather, Slipczuk and colleagues (2009) have illustrated two distinct time-restricted 
windows for RAP-sensitivity in the consolidation of fear memory, immediately around 
the time of conditioning and again 3 hours post-training. Those results support a ro le for 
mTOR signalling in initial fonnation, but not the protracted cellular consol idation-like 
events that contribute to memory persistence observed 12 to 24 hours post-training, such 
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as increased expression of extracellular signal-regulated kinase 2 (ERK2), c-FOS, Akt, 
Homer la, and a calcium/calmodulin-dependent protein kinase kinase (aCamKII) 
(Bekinschtein eta!., 20 I 0). However, there are a number of explanations for the 
differences in results between these studies and the findings presented here. First, in the 
aforementioned studies, RAP infusion was restricted to the dorsal hippocampus; here 
RAP was administered systemically, allowing for wider distribution of the drug. Also, 
while the dorsal hippocampus is integral to fear memory formation, evidence suggests it 
is not necessary for the unconditioned stimulus - conditioned stimulus (US-CS) 
association in fear learning (Matus-Amat, Higgins, Barrientos, & Rudy, 2004). Secondly, 
different types of fear learning paradigms were examined. In these other studies 
(Bekinschtein et a!., 2008; Slipczuk et a!., 2009), contextual fear conditioning was 
examined using an inhibitory avoidance task, while the present experiments investigated a 
cued-based fear memory, which appears not to be mediated by the hippocampus, as direct 
infusion of RAP into the dorsal hippocampus immediately after training failed to impair 
auditory fear memory retention (Gafford eta!. , 20 11 ). 
RAP was also assessed for whether it has long-lasting effects on fear memory 
consolidation. In agreement with Latta! and Abel (2004), it was found that AN ISO 
treatment effaced memory when probed 21 days after training and drug injection. 
Surprisingly, post-training RAP treatment had no enduring effect on memory when tested 
2 1 days later. Thus, it appears that the effects of RAP on memory consolidation gradually 
decay over time. While unlikely, the dosage of RAP ( 40 mg/kg) used to disrupt 
consolidation may not have been optimal to efface long-term retention. Nevertheless, the 
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concentration of RAP used in this study has been shown to optimally decrease memory, 
while sparing any patent changes to locomotion, anxiety, or nocieception (Blundell et al. , 
2008). RAP is also a potent immunosuppressant, thus, increasing the dosage may raise the 
risk of injury and disease due to an elevated immunocompromised state. Further, while 
RAP did not completely block retention, the effect sizes in these experiments (both 
consolidation and reconsolidation) are comparable to other published studies using RAP 
and other protein synthesis inhibitors, with memory seldom ever being completely 
effaced by these agents (Bourtchouladze et al. , 1998; Debiec & LeDoux, 2004; Parsons et 
al., 2006). 
4.2 Reconsolidation of Auditory Fear Memory 
As with consolidation, the reconsolidation experiments confirm and augment the 
findings of Parsons et a!. (2006) for an effect of RAP on auditory cued fear memory. 
Indeed a one-trial memory reactivation, combined with systemic RAP-treatment dampens 
subsequent fear memory expression. Moreover, the amnestic effects of RAP occur only in 
conjunction with re-exposure to the cue, as treatment in the absence of reactivation does 
not hinder memory. Nevertheless, these systemic effects on reconsolidation are in 
contrast to another study that found no effect from systemic RAP treatment (40 mg/kg) on 
either consolidation or reconsolidation of a cued fear memory (Glover et al. , 201 0). 
However, the discrepancies between this study and Glover et al. (20 I 0) might be due the 
use of different modalities of CS (auditory vs. olfactory) , and a different measure of fear 
(treezing vs. fear potentiated startle). 
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Unlike the case of consolidation, a single systemic injection of RAP paired with 
memory reactivation blocked subsequent recall when measured 21 days after retrieval. 
Moreover, these effects were of equal magnitude to ANI SO, a drug that empirically 
defines reconsolidation (Nader et al. , 2000). Numerous reports have revealed dissociative 
recruitment of various substrates in either the consolidation or reconsolidation of 
memory, indicating that reconsolidation is not a complete recapitulation of the 
mechanisms of consolidation (Duvarci et al. , 2008; Lee et al. , 2004; Parsons et al. , 2006). 
This possibility cannot be overlooked in the present data. Indeed, these results parallel 
those of Blundell et al. (2008), exhibiting a lasting effect on reconsolidation, and 
expanding the generality of RAP efficacy on reconsolidation from contextual fear 
memory to cued, auditory fear memory. As such, it should be noted that unlike this 
present study, Blundell et al. (2008) did not characterize the long-term effects of RAP on 
memory consolidation, only examining retention 24 hours post-training. Thus, it is 
unclear whether mTOR is necessary in the enduring expression of contextual memory. 
Having established that mTOR blockade immediately after memory retrieval 
hinders subsequent memory retention similar to the motif established in the consolidation 
experiments, albeit having a longer-lasting effect, subsequent experiments sought to 
detennine whether reconsolidation recapitulates late phase sensitivity to RAP treatment. 
To the best of my knowledge, this is the first study to investigate whether any protracted 
molecular events important for retention occur hours after memory reactivation. 
Analogous to consolidation, reconsolidation of auditory fear memory demonstrates two 
time-windows of RAP-sensitivity to subsequent memory recall , first immediately after 
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training and 12 hours thereafter. These findings suggest recurrent waves of RAP-
sensitivity in the reconsolidation of auditory fear memory, with the latter phase possibly 
contributing to protracted cellular events required for persistence of the re-stabilized 
memory trace. It is unknown whether other molecular substrates germane to learning and 
memory, especially those that exhibit biphasic patterns of activation and susceptibility to 
pharmacological intervention during consolidation, demonstrate similar temporal patterns 
as mTOR in reconsolidation; as evidenced through RAP inhibition of this translational 
regulator. Further research will be needed to address these questions. 
4.3 Putative mTOR Signal-Transduction Pathways in Long-Lasting Forms of 
Plasticity 
In neurons, mTOR is present post-synaptically in dendrites where it governs local 
protein synthesis, essential for long-lasting fonns of synaptic potentiation and memory 
(Jourdi et a!. , 2009; Takei eta!. , 2004; Vickers, Dickson, & Wyllie, 2005). Recent studies 
have begun to elucidate the signal-transduction pathways that activate the mTOR 
pathway in response to conditioning, and the concomitant proteins thought to stabilize 
long-lasting tonns of plasticity. BON F is regarded as a facilitator of enduring plastic 
changes (Bekinschtein et a! 2007a; Patterson eta!. , 1996; Tyler, Alonso, Bramham, & 
Pozzo-Miller, 2002). Both in vitro and in vivo studies have shown that BDNF affects 
behavioural and synaptic plasticity through RAP-sensitive signalling (Spliczuk eta!., 
2009; Tang eta!. , 2002). Thi s is most likely achieved through local dendritic up-
regulation of translational machinery and protein synthesis, as BDNF mediates these 
alterations in an mTOR-sensitive manner (Takei et a!., 2004). Specifically, BDNF-mTOR 
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signalling increases GluRI expression. GluRI is a subunit ofglutamatergic a-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, necessary for memory 
formation and other synaptic plastic changes (Fortin et al., 20 12; Schratt, Nigh, Chen, Hu, 
& Greenberg, 2004; Slpiczuk et al. , 2009). Similarly to BDNF, glutamatergic activation 
of N-methyl-0-aspartate (NMDA) receptors post-synaptically appears to be another 
upstream mediator, intimately coupled to mTOR-dependency, for activity-dependent 
plasticity and dendritic protein synthesis (Gong et al. , 2006; Takei et al 2004; Vickers et 
al., 2005). MTOR also regulates the translation of other transcripts triggered by 
conditioning, essential to behavioural and synaptic plasticity, such as microtubule-
associated protein 2 (Map2), and aCamKII (Gong et al. , 2006; Miller et al. , 2002). 
However, determination of whether these mTOR-dependent proteins are even translated 
in response to the same or different extracellular or intrinsic signals during protracted 
consolidation-like events hours after training, or during the biphasic RAP-sensitive time 
windows during reconsolidation established here still needs to be addressed. 
4.4 Experimental Conditioning Protocol as a Cogent Model of PTSD and Tool to 
Study the Neurobiology of Learning and Memory 
Experiments l and 2 demonstrated that the single session, two-trial, auditory fear 
conditioning procedure was efficacious fo r establishing a strong leamed cue association, 
comparable to other studies using similar protocols (Gamache, Pitman, & Nader, 20 12; 
Kishioka, Uemura, Fukushima, & Mishina, 20 13; Tang et al. , 200 1). The two-trial 
leaming protocol was also revealed to maximize the magnitude of the leam ed response. 
Additionally, the stimulus intensity (footshock amperage) used did not induce a state of 
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generalized fear in any experiment, as evidenced by the lack of any significant freezing 
behaviour in all control and experimental groups upon exposure to the novel chamber 
prior to tone presentation for memory testing. The generalization phenomenon is a 
potential source of contamination to the conditioned auditory fear response, often 
observed with higher range footshock intensities (Baldi, Lorenzini, & Bucherelli, 2004). 
Altogether, these data establish a confidence level that the conditioning procedure is 
sufficient and robust in inducing a specific conditioned (auditory) fear response which 
can be used to adequately and consistently examine the neurobiology of consolidation and 
reconso I idation. 
Even though no animal model is plenary in simulating PTSD, specific symptoms 
can be mimicked in diverse models of PTSD (Adamec, Head, Soreq, & Blundell, 2008; 
Blundell et a!., 2008; Cohen, Kaplan, Matar, Loewenthal, Kozlovsky, & Zohar, 2006; 
Jobim eta!., 20 l2a). Auditory fear conditioning is a valid heuristic model of PTSD, 
accurately capturing the fear that accompanies reminders of the traumatic event 
(Siegmund & Wotjak, 2006; Zovkic & Sweatt, 2013). Moreover, while the information 
gleaned here and from similar studies provides important insights into the neurobiology 
of learning and memory, it also supports a cogent model for treatment of PTSD, and other 
learned emotional disorders through pharmacological exploi tation of unstable reactivated 
memories. These experiments provide important pre-clinical information concerning the 
pharmacological treatment of acquired traumatic memories. RAP was demonstrated to 
effectively reduce conditioned responding in a long-lasting manner after a one trial 
reactivation session coupled with drug treatment. Additionally, a second possible 
therapeutic time-point for RAP treatment 12 hours after retrieval was demonstrated. 
Importantly, like the effects of RAP to the reconsolidation of contextual fear memory 
(Blundell et a!. 2008), reactivation of the memory prior to treatment is necessary, as 
retrograde amnesia was not observed when RAP was administered in the absence of 
reactivation, an important aspect for treatment specifi city in reducing the emotional 
intensity of the traumatic memory without interfering with other cognitive processes. 
4.5 General Conclusions 
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Collectively, the evidence presented here agrees with other published studies that 
mRNA translational regulation by mTOR is critically involved in the consolidation and 
reconsolidation of memory. Furthermore, this study is the first to demonstrate recurrent, 
protracted consolidation and reconsolidation-like RAP-sensitive events that contribute to 
the fo rmation and reconsolidation of fear memory. Finally, these reconsolidation 
experiments provide a tenable model for a therapeutic approach to decreasing the 
emotional valence of traumatic memories using an FDA-approved drug that could 
potentially be used in patients suffering tl·om PTSD. 
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Figure Captions 
Figure l. Single session, two-trial auditory fear procedure optimizes associability and 
maximizes the conditioned response. (A) Only animals that received the tone-shock (TS; 
n = 12) pairing with each trial during training exhibited the conditioned fear response 
during 48 hours later; controls (NS; n = 4) [mixed AN OVA: main effect of condition, 
day, and interaction effect of condition and day, all Fs ( I, 14) > 20.386, p < .00 I; follow-
up t-test: t (14) = -4.5 15, p < .001]. (B) Increasing the number of trials in a single training 
session does not increase the conditioned freezing response [mixed ANOVA: main effect 
of day F (1 , 28) = 347.433, p < .001 , but no main effect ofnumber oftrials or interaction 
effect of number of trials and day, both F (3 , 28) = 1.447, p = .250] when tested for 48 
hours later. The number for before each TS group indicates the number ofTS pairings. N 
= 8 tor all groups. Data are expressed as mean (±SEM) of percent freezing for fear 
memory probe sessions (and training where applicable) in all figures . Asterisks represent 
p < .05 for all figures. 
Figure 2. Systemic rapamycin impairs auditory fear consolidation. (A) Rapamycin 
injected immediately following training disrupts recall 48 hours later [mixed ANOVA: 
main effect of drug F (1 , 20) = 4.553, p = .045, main effect of day F ( I, 20) = 67.807, p < 
.00 I, interaction effect of drug and day F ( I, 20) = 4.553, p = .045]. Post hoc comparison 
(t-test) of vehicle (VEH) and rapamycin-treated (RAP) animals for freezing behaviour at 
test [t (20) = -2.1 34, p = .045]. N = 11 fo r each group. (B) Rapamycin treatment 
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immediately after training does not impair recall when probed I hour later (STM, t-test: t 
(20) = 0.054, p = .958), but still attenuates fear expression 48 hours after training (L TM, 
t-test: t (20) = 2.225, p = .038). N = I 0 (VEH), 12 (RAP). (C) Injection of rapamycin 30 
minutes prior to testing does not alter fear memory retrieval when probed 48 hours post-
training [mixed AN OVA: main effect of day F (I , 22) = 130.023, p < .001, but no 
significant main effect of drug or drug by day interaction, all Fs (1, 22) < 0.816, all p > 
.05). N = 12 for each group. 
Figure 3. The effects of systemic rapamycin following conditioning are not enduring. 
Systemic injection of anisomycin (AN ISO), but not rapamycin (RAP) or vehicle (VEH), 
immediately after training significantly reduced fear memory retention when probed 2 1 
days later in the absence of drug [mixed AN OVA: main effect of drug F (2, 33) = 16.056, 
p < .001 , main effect of day F (1 , 33) = 84.533 , p < .001, and interaction effect of drug 
and day F (I , 33) = 14.91 5, p < .001 ; post-hoc Fisher's LSD ANISO vs. RAP, p < .001; 
AN ISO vs. VEH, p < .00 I ; RAP vs. VEH, p = .529). N = 12 for all groups. 
Figure 4. Systemic rapamycin 12 hours after acquisition impairs fear memory fonnation. 
Injection of rapamycin 12 hours (B), but not 3 (A) or 24 (C) hours following auditory fear 
conditioning significantly hinders retention when probed 48 hours post-training [mixed 
ANOV A: main effect of drug F (I , 65) = 6.338, p = .014 and main effect of day F (I, 65) 
= 158.254, p < .00 I] . Post hoc comparisons (t-tests) for freezing behaviour at probe of 
46 
vehicle (VEHO versus rapamycin (RAP) for post-training treatment at 3, 12, or 24 hours [t 
(22) = 0.645, p = .526; t (21) = 2.253, p = .035 ; t (22) = 1.419, p = .170] respectively. N = 
12 for all groups, except for VEH-12, n = 11. 
Figure 5. Systemic rapamycin impairs fear memory reconsolidation. (A) Single trial post-
retrieval rapamycin dampens subsequent fear recall. Post-reactivation rapamycin inhibits 
subsequent fear memory 24 hours after retrieval, 72 hours post-training. A mixed 
ANOV A revealed a main effect of day [F (2, 54) = 45.573 , p < .00 I] , and a significant 
interaction effect of drug and day [F (2, 54) = 4.206, p = .020], while the main effect of 
drug approached, but did not reach significance [F (1 , 27) = 3.659, p = .066]. Post hoc 
comparisons (t-tests) of vehicle (VEH) and rapamycin (RAP) treated animals for freezing 
behaviour on test days 2 ( 48 hours post-training) and 3 (72 hours post-training) [t (27) = 
0.151, p = .88 1; t (27) = -2.8 17, p = .009, respectively]. Hour zero delineates the training 
session (first 2 minutes in conditioning chambers; no ditTerence between groups during 
training, t-test, p > .05). N = 10 (VEH), 12 (RAP). (B) Reactivation ofthe fear memory is 
necessary for the effects of rapamycin upon subsequent recall. Rapamycin treatment in 
the absence of reactivation does not alter fear memory expression 24 hours after drug 
treatment, 72 hours post-training (VEH vs. RAP, p > .05). N = 12 for both groups. 
Figure 6. Administration of rapamycin fo llowing fear memory reactivation has long-
lasting etTects, equivalent to anisomycin. A single trial fear memory reactivation paired 
47 
with rapamycin (RAP) or anisomycin (AN ISO) diminished subsequent recall when 
probed 2 1 days later in the absence of drug [mixed ANOV A: main effect of drug F(2, 33) 
= 3.609, p = .038, main effect of day F (2, 66) = 45.396, p < .001 , interaction effect of 
drug and day F ( 4, 66) = 1.853, p = .129; Post hoc Fisher 's LSD tests: VEH vs. RA P, p = 
.018, VEH vs. ANJSO, p = .042, RAP vs. AN ISO, p = .7 10]. Day zero delineates the 
training session (first 2 minutes in conditioning chambers; no significant difference 
between groups during training or reactivation (Day 2), Post hoc Fisher's LSD tests (data 
not shown): all p > .05). N = 12 for all groups. 
Figure 7. Systemic rapamycin treatment twelve hours after reactivation impairs fear 
memory reconsolidation. Mice receiving a single rapamycin (RAP-1 2) injection at 12 
hours (A), but not at 24 hours (B) post-reactivation (RA P-24), show significantly 
decreased recall 48 hours atter retrieval, 96 hour post-training, relative to vehicle (VEH-
12, 24) counterparts [mixed ANOVA: main etfect ofdrug F (1 , 43) 4 .078, p = .050, and 
main effect of day F (2, 86) = 89.903 , p < .001 ]. Post hoc comparisons (t-tests) of vehicle 
versus rapamycin-treated mice for 12 and 24 hour delay groups [t (21) = 2.460, p = .023 , t 
(22) = 0. 190, p = .85 1, respectively] on final day of testing. N = 12 for all groups, except 
for RA P- 12 , n = 11. 
Figure 1. 
A. 
60 
~ 40 
N 
Q) 
Q) 
'-
LL 
~ 20 0 
* 
0--------~------~ 
B. 
80 
60 
C) 
c 
N 
<1> 40 <1> 
'-
LL 
~ 0 
20 
0 
48 
Figure 2. 
A. 
B. 
c. 
C) 
c::: 
";::j 30 
Q) 
Q) 
..... 
LL 20 
~ 0 
C) 
c::: 
N 
Q) 
Q) 
..... 
LL 
~ 0 
C) 
.5: 
N 
Q) 
Q) 
..... 
LL 
~ 
10 
0 
49 
* 
~<v¥:- <I 
D VEH * 
-RAP 
Figure 3. 
50 
40 
C) 
t: 
·N 30 
Q) 
Q) 
'-
u. 20 
~ 0 
o ........ .....__---.. _ __.___ 
so 
* 
Figure 4. 
A. 
B. 
C. 
40 
30 
C) 
c: 
N 
:R 20 
... 
u.. 
'cf!. 
C) 
c: 
N 
Q) 
Q) 
... 
u.. 
'cf!. 
C) 
.5 
N 
Q) 
Q) 
... 
u.. 
10 
51 
* 
Figure 5. 
A. 50 
40 
C) 
s:: 30 ·-N 
<U 
<U 
'-
LL 20 
~ 0 
10 
0 
B. 
-e- VEH 
---
RAP 
0 25 50 
Hours 
75 
D VEH 
-RAP 
52 
53 
Figure 6. 
50 -e- VEH 
.... ANI SO 
40 ....... RAP 
C) 
c: 
·N 30 
Q) 
Q) 
I-
LL 20 
~ 0 
10 
0 
0 5 10 15 20 25 
Days 
Figure 7. 
A. 
B. 
* 
o~-L--~~-------
40 
30 
C) 
t: 
o~-L--~----~---
54 
I 




